AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.310

-0.015-4.62%

Volume:1.17M

Turnover:368.46K

Market Cap:186.12M

PE:-11.08

High:0.330

Open:0.325

Low:0.307

Close:0.325

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:0.65

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.028

EPS(LYR):-0.024

ROE:-594.54%

ROA:-58.27%

PB:-110.71

PE(LYR):-13.11

Loading ...

Overview Company News Filings

Dimerix - Trading Halt Requested Pending Non-dilutive Funding and Asset Acquisition Announcements

THOMSON REUTERS

Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients

MT Newswires Live

Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says

MT Newswires Live

BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines

Dimerix Ltd - Dimerix Licenses Dmx200 to Everest for China and Asia Region

THOMSON REUTERS

Everest Medicines - Agreement With Dimerix to Develop & Commercialize Dmx-200 in Greater China, South Korea and Southeast Asia

THOMSON REUTERS

Everest Medicines - Deal Includes $10 Mln Upfront, up to $30 Mln Development Milestones, $300 Mln Sales Milestones, 10%-15% Royalties

THOMSON REUTERS

Everest Medicines licenses Dimerix’s DMX-200 rights for Greater China, South Korea and Southeast Asia in deal worth up to USD 340 million

BRIEF-Dimerix Seeks Trading Halt

Dimerix - Trading Halt Requested Pending Out-Licensing Agreement Announcement

THOMSON REUTERS

Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says

MT Newswires Live

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says

MT Newswires Live

Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys

MT Newswires Live

Dimerix's Alignment With US FDA on Phase Three 3 Disease Trial Endpoints, Review Process Suggests Productive Ongoing Dialogue, Euroz Hartleys Says

MT Newswires Live

Dimerix to Conduct Blinded Review of Phase Three Kidney Disease Trial Data

MT Newswires Live

BRIEF-Dimerix To Conduct Review Of Action3 Statistical Assumptions

Dimerix Ltd - Dimerix to Conduct Review of Action3 Statistical Assumptions

THOMSON REUTERS

Dimerix Completes Patient Dosing in Phase 3 Kidney Disease Trial; Shares Up 3%

MT Newswires Live

Indonesia's Soekarno-Hatta Reschedules 39 Middle East Flights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/DXB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.31,"timestamp":1787292720000,"preClose":0.325,"halted":0,"volume":1167459,"delay":0,"changeRate":-0.04615384615384619,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.027967,"marketStatus":"Not Yet Opened","change":-0.015,"latestTime":"08-21 16:12:00 AEST","open":0.325,"high":0.33,"low":0.307,"amount":368460,"amplitude":0.070769,"askPrice":0.32,"askSize":26000,"bidPrice":0.305,"bidSize":51931,"shortable":3,"etf":0,"ttmEps":-0.027967,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.325,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.6515115207611286,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.325,"auctionPrice":0.31,"auctionVolume":81184,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600775}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-58.27%","roe":"-594.54%","lyrEps":-0.023645,"volumeRatio":0.6515115207611286,"shares":600396776,"dividePrice":0,"high":0.33,"amplitude":0.070769,"preClose":0.325,"low":0.307,"week52Low":0.157,"pbRate":"-110.71","psRate":"25.10","week52High":0.665,"institutionHeld":0,"latestPrice":0.31,"committee":0.332743,"eps":-0.027967,"divideRate":0,"volume":1167459,"delay":0,"ttmEps":-0.027967,"open":0.325,"prevYearClose":0.55,"prevWeekClose":0.31,"prevMonthClose":0.245,"prevQuarterClose":0.205,"fiveDayClose":0.295,"twentyDayClose":0.25,"sixtyDayClose":0.175,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651482390","title":"Dimerix - Trading Halt Requested Pending Non-dilutive Funding and Asset Acquisition Announcements","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651482390?lang=en_us&edition=fundamental","pubTime":"2026-07-15 06:42","pubTimestamp":1784068961,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","DXB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650317943","title":"Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2650317943","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650317943?lang=en_us&edition=fundamental","pubTime":"2026-07-09 11:52","pubTimestamp":1783569144,"startTime":"0","endTime":"0","summary":"Dimerix  said eligible patients with focal segmental glomerular sclerosis who complete treatment in its phase three clinical trial and open-label extension study will be able to continue receiving investigational therapy DMX-200 through post-trial access programs in key territories, according to a Thursday Australian bourse filing.The company said access will be provided to patients whose treating physicians determine that ongoing therapy is appropriate and that no suitable alternative is available through expanded access, compassionate use, special access, or other applicable regulatory pathways, subject to local regulations, per the filing.The company's commercial partners will handle market access and supply costs for DMX-200 in their territories, while it will assume these responsibilities in territories where no commercialization partner has been appointed, the filing added.The company's shares rose past 2% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","DXB.AU","POST","BK4212","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644792742","title":"Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644792742","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644792742?lang=en_us&edition=fundamental","pubTime":"2026-06-17 11:08","pubTimestamp":1781665732,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) has added incremental value through its licensing deal with Everest Medicines while strengthening its funding position and validating DMX-200's commercial potential, Euroz Hartleys s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","BK7067","FSGS","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643738819","title":"BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2643738819","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643738819?lang=en_us&edition=fundamental","pubTime":"2026-06-16 10:36","pubTimestamp":1781577361,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines** Shares of Australia's Dimerix DXB.AX rise as much as 51.5% to A$0.250, their highest since April 30** Clinical stage b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL6N42O05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK1161","01952","BK7501","BK1583","BK1574","BK7508","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643784076","title":"Dimerix Ltd - Dimerix Licenses Dmx200 to Everest for China and Asia Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2643784076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643784076?lang=en_us&edition=fundamental","pubTime":"2026-06-16 08:21","pubTimestamp":1781569287,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42N0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01952","BK7501","BK7508","DXB.AU","BK7067","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643814757","title":"Everest Medicines - Agreement With Dimerix to Develop & Commercialize Dmx-200 in Greater China, South Korea and Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2643814757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643814757?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:56","pubTimestamp":1781564191,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N0LL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1161","BK7067","01952","BK7508","DXB.AU","BK7501","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643814207","title":"Everest Medicines - Deal Includes $10 Mln Upfront, up to $30 Mln Development Milestones, $300 Mln Sales Milestones, 10%-15% Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2643814207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643814207?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:56","pubTimestamp":1781564191,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N0LL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","01952","BK1161","BK1574","BK7067","BK7508","DXB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643812867","title":"Everest Medicines licenses Dimerix’s DMX-200 rights for Greater China, South Korea and Southeast Asia in deal worth up to USD 340 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2643812867","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643812867?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:55","pubTimestamp":1781564151,"startTime":"0","endTime":"0","summary":"Everest Medicines licenses Dimerix’s DMX-200 rights for Greater China, South Korea and Southeast Asia in deal worth up to USD 340 million. Everest Medicines signed an exclusive license with Dimerix on June 16, 2026 to develop, commercialize DMX-200 in Greater China, South Korea, Southeast Asia.Upfront payment set at USD 10 million; development, regulatory milestones up to USD 30 million; sales milestones up to USD 300 million.Deal includes tiered royalties of 10% to 15% on future annual net sales.DMX-200 is a CCR2 small-molecule inhibitor in a pivotal Phase 3 trial for focal segmental glomerulosclerosis; holds FDA, EMA orphan-drug designations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLTzzyl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK7508","BK7067","BK7501","BK1161","BK1583","DXB.AU","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228788","title":"BRIEF-Dimerix Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228788?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:54","pubTimestamp":1781481269,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Seeks Trading Halt June 15 (Reuters) - Dimerix Ltd DXB.AX:TRADING HALT REQUESTED PENDING OUT-LICENSING AGREEMENT ANNOUNCEMENTFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nFWN42K0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643285092","title":"Dimerix - Trading Halt Requested Pending Out-Licensing Agreement Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2643285092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643285092?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:14","pubTimestamp":1781478847,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nFWN42K0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","DXB.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632699919","title":"Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2632699919","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632699919?lang=en_us&edition=fundamental","pubTime":"2026-05-01 10:45","pubTimestamp":1777603552,"startTime":"0","endTime":"0","summary":"Dimerix's  potential access to $50 million in non-dilutive funding could lead to it having up to AU$96.6 million in combined cash and non-dilutive funding available, which would be sufficient to fully fund the ongoing phase three trial and dispel any near-term capital raising risk, Euroz Hartleys said in a note on Thursday.It indicated this would not be traditional debt funding, but is rather repayable from future milestone payments and/or royalties.The commercial opportunity remains significant and unchanged, Euroz Hartleys added.The investment firm maintained its speculative buy rating on Dimerix with a price target of AU$1.35 per share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK7067","DXB.AU","DBB"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2630234053","title":"BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE","url":"https://stock-news.laohu8.com/highlight/detail?id=2630234053","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630234053?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:17","pubTimestamp":1777342620,"startTime":"0","endTime":"0","summary":"An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered  to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion. To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint. As previously announced, the FDA has agreed that proteinuria is an appropriate endpoint for full regulatory approval for DMX-200 in ACTION3. Evidence from the PARASOL working group, together with the recent FDA approval of an FSGS therapy in the US based on the proteinuria endpoint, further supports proteinuria as the prim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/blinded-assessment-of-action3-statistical-assumptions-complete-302755001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARB.AU","BK7051","BK7501","ARB","BK7508","DXB.AU","FSGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627999814","title":"Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2627999814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627999814?lang=en_us&edition=fundamental","pubTime":"2026-04-14 12:01","pubTimestamp":1776139286,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) is poised to benefit from the US Food and Drug Administration's recent approval of Travere Therapeutics' sparsentan drug to treat focal segmental glomerulosclerosis, a rare kidney di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK7501","BK7508","BK4007","BK4539","LENZ","BK4588","LABU","DXB.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625399752","title":"Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2625399752","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625399752?lang=en_us&edition=fundamental","pubTime":"2026-04-08 13:55","pubTimestamp":1775627705,"startTime":"0","endTime":"0","summary":"Dimerix  is protected from recent US pharmaceutical tariff changes due to its out-licensing model, Euroz Hartleys said in a note on Tuesday.The Trump administration imposed tariffs on imported patented pharmaceuticals under Section 232 of the Trade Expansion Act, citing national security risks in the pharmaceutical supply chain.The standard tariffs are 100%, with reduced rates of 15% for the European Union, Japan, South Korea, Switzerland, and Liechtenstein, and 10% for the United Kingdom. The administration is allowing a transition period of 120 days for large companies and 180 days for small companies before these tariffs take effect.Euroz Hartleys notes that the company's out-licensing model shields it from higher manufacturing costs, with royalties and milestone payments tied to revenue rather than production expenses, meaning the US tariffs are not expected to affect the company's financial forecasts.Euroz Hartleys maintained its speculative buy rating on Dimerix with a price targ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","DXB.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620741030","title":"Dimerix's Alignment With US FDA on Phase Three 3 Disease Trial Endpoints, Review Process Suggests Productive Ongoing Dialogue, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2620741030","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620741030?lang=en_us&edition=fundamental","pubTime":"2026-03-17 12:39","pubTimestamp":1773722358,"startTime":"0","endTime":"0","summary":"Dimerix's (ASX:DXB) decision to conduct a blinded review of the Action3 phase 3 study data to confirm statistical assumptions of the primary endpoint after reaching alignment with the US Food and Drug","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LABU","BK7508","DXB.AU","BK7067","BK7501","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619805884","title":"Dimerix to Conduct Blinded Review of Phase Three Kidney Disease Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2619805884","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619805884?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:14","pubTimestamp":1773627284,"startTime":"0","endTime":"0","summary":"Dimerix  is set to conduct a blinded review of the ACTION3 phase three study data to confirm statistical assumptions of the primary endpoint during March, according to a Monday Australian bourse filing.It will use methods specified in the study's statistical analysis plan previously submitted to the US Food and Drug Administration .The phase 3 Action3 trial is a placebo-controlled study of the efficacy and safety of its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis who are receiving a stable dose of a blood pressure medication known as an angiotensin II receptor blocker. It is designed to capture evidence of proteinuria reduction and kidney function during the trial, aimed at generating sufficient evidence to support marketing approval.The FDA previously confirmed that the proposed primary endpoint of percent reduction in proteinuria compared to placebo is suitable to support traditional approval of DMX-200 via the 505 pathway, with estimated glomerular fil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619484775","title":"BRIEF-Dimerix To Conduct Review Of Action3 Statistical Assumptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484775","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484775?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:07","pubTimestamp":1773623244,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix To Conduct Review Of Action3 Statistical AssumptionsMarch 16 (Reuters) - Dimerix Ltd DXB.AX:DIMERIX TO CONDUCT REVIEW OF ACTION3 STATISTICAL ASSUMPTIONSFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4011FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","DXB.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619485692","title":"Dimerix Ltd - Dimerix to Conduct Review of Action3 Statistical Assumptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2619485692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619485692?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:29","pubTimestamp":1773610167,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN4011FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618600488","title":"Dimerix Completes Patient Dosing in Phase 3 Kidney Disease Trial; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600488","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618600488?lang=en_us&edition=fundamental","pubTime":"2026-03-10 11:52","pubTimestamp":1773114760,"startTime":"0","endTime":"0","summary":"Dimerix  said the phase 3 Action3 trial of its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis completed dosing the last adult patient recruited into the study, bringing the final enrollment to 333 adult patients, according to a Tuesday Australian bourse filing.Focal segmental glomerulosclerosis is a kidney disease characterized by progressive scarring in parts of the glomeruli, leading to proteinuria, progressive loss of kidney function, and often end-stage renal disease.The study is closed to further recruitment of adult patients, while the recruitment of pediatric patients remains ongoing as an independent group in the trial, the filing said.The full two-year study will assess the efficacy and safety of DMX-200 in focal segmental glomerulosclerosis patients when dosed in combination with standard-of-care blood pressure medication known as an angiotensin II receptor blocker over two years, per the filing. It is expected to be completed in March 2028.The com","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616038420","title":"Indonesia's Soekarno-Hatta Reschedules 39 Middle East Flights","url":"https://stock-news.laohu8.com/highlight/detail?id=2616038420","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616038420?lang=en_us&edition=fundamental","pubTime":"2026-03-02 16:10","pubTimestamp":1772439012,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-The Soekarno-Hatta International Airport  Branch Office of PT Angkasa Pura Indonesia  in Tangerang, Banten, adjusted the departure schedules of 39 flights to the Middle East that had been postponed due to the conflict in the region.Aziz Fahmi Harahap, the Acting Assistant Deputy for Communication and Legal Affairs at Soekarno-Hatta International Airport, said on Monday in Tangerang that, as of 10:00 AM local time, there were 39 scheduled flights on the Middle East route. This consisted of 20 arrivals and 19 departures, including 38 regular flights and one charter flight.\"Following up on developments in flight operations on the Middle East route, we are reporting this based on route permit data issued by the relevant authorities and updated as of 10:00 AM LT,\" he said.","market":"sg","thumbnail":"https://statik.tempo.co/data/2025/12/23/id_1449385/1449385_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/12/23/id_1449385/1449385_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2090117/indonesias-soekarno-hatta-reschedules-39-middle-east-flights","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2090117/indonesias-soekarno-hatta-reschedules-39-middle-east-flights","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK7501","BK7067","MED","BK7508","DXB","BK4183","MED.AU","BK4532","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}